Conferences - Results from #780

Viewing 781-800 of 11869 articles

APCCC 2024: Which Patients with mHSPC Can Be Offered a Treatment Break (De-Escalation Strategies) and How to Manage the Break?

APCCC 2024: Escalation Strategies in Patients with mHSPC and an Unfavourable PSA Decline – Is More Better?

APCCC 2024: Update on the IRONMAN Project

APCCC 2024: Debate: How to Best Manage a Fit Patient with High-Risk Localised and Locally Advanced Prostate Cancer? Surgery as Radical Local Treatment (As Part of a Multimodality Approach)

APCCC 2024: In Which Patients with Metachronous Low-volume mHSPC Do You Recommend “total Therapy”?

APCCC 2024: In Which Patients with Synchronous Low-Volume mHSPC Do You Recommend “Total Therapy”?

APCCC 2024: Should the Primary Be Treated in Synchronous High-Volume mHSPC

APCCC 2024: Radiation Therapy Schedules and Fields for High-Risk and Locally Advanced Prostate Cancer

APCCC 2024: Introduction to mHSPC – What Are Relevant Prognostic/Predictive Factors for the Management of Patients?

APCCC 2024: Synchronous Low-volume mHSPC – In Which Patients Do You Recommend Combination Systemic Therapy Plus Local Treatment of the Primary and in Which Patients is ADT Alone Plus Radiotherapy Enough?

APCCC 2024: In Patients Who Receive Salvage Radiation Therapy for BCR, Who Needs Additional Systemic Therapy, What and for How Long?

APCCC 2024: Which Patients with High-Risk First BCR after Radical Prostatectomy Are Candidates for Systemic Therapy Alone Without Local Salvage Radiotherapy?

APCCC 2024: Second BCR (Without Correlate on NGI) After Salvage Radiation And/or After Metastases Directed Therapy: How to Manage These Patients?

APCCC 2024: In Patients with BCR and Positive Lesion(s) in the Pelvis – Stereotactic or Whole Pelvis Radiotherapy?

APCCC 2024: How to Select Patients with Biochemical Relapse in Whom Salvage Radiation Therapy Can Be Postponed?

APCCC 2024: Are Some Patients with Biochemical Recurrence (After Radiotherapy And/or Radical Prostatectomy) Candidates for Androgen Receptor Antagonist Monotherapy and How to Manage the Systemic Therapy?

APCCC 2024: How to Manage Patients with PSA Persistence Following Radical Prostatectomy?

APCCC 2024: Debate: How to Best Manage a Fit Patient with High-Risk Localised and Locally Advanced Prostate Cancer? Radiation Therapy as Radical Local Treatment (As Part of a Multimodality Approach)

APCCC 2024: High-Risk and Locally Advanced Prostate Cancer in the Context of Current Diagnostic and Therapeutic Options – Which Is the Ideal Definition to Use for Clinical Practice?

APCCC 2024: Regional Lymph Node Staging for High-Risk and Locally Advanced Prostate Cancer – What Should Be the Standard?

35
36
37
38
39
40
41
42
43
44